pre-IPO PHARMA

TAG: ASH

Dec 13, 2022

Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting


Dec 12, 2022

Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting


Dec 12, 2022

JW Therapeutics Presents Latest Clinical Data on Carteyva in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting


Dec 12, 2022

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting


Dec 12, 2022

Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting



Dec 11, 2022

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event


Dec 10, 2022

Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)


Dec 10, 2022

Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting


Dec 9, 2022

Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)


Dec 6, 2022

Kurome Therapeutics Announces Oral and Poster Presentations on Dual IRAK1/4 Inhibitors at American Society of Hematology Annual Meeting



Nov 28, 2022

GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)


Nov 4, 2022

ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting


Nov 3, 2022

Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting


Nov 3, 2022

EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition


Nov 3, 2022

Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting



Nov 3, 2022

Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting


Nov 3, 2022

ICHNOS SCIENCES DATA SELECTED FOR PRESENTATION AT THE 64TH ASH ANNUAL MEETING


Nov 3, 2022

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition


Nov 3, 2022

Orca Bio to Present Four Abstracts at the 64th American Society of Hematology Annual Meeting, Including Updated Relapse-Free Survival Data with Orca-T and the First Clinical Data for Orca-Q


Dec 14, 2021

JW Therapeutics Presents Primary Clinical Response on Carteyva (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting



Dec 13, 2021

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition


Dec 13, 2021

Rafael Pharmaceuticals Announces Published Data on CPI-613 (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition


Dec 13, 2021

Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting


Dec 13, 2021

Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting


Dec 13, 2021

Data on Bantam Pharmaceutical's Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual Meeting of the American Society of Hematology



Dec 12, 2021

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting


Dec 11, 2021

Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting


Dec 11, 2021

Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)


Dec 11, 2021

Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting


Dec 8, 2021

Metagenomi to Present Preclinical In Vivo and Ex Vivo Gene-Editing Data at the 63rd American Society of Hematology (ASH) Annual Meeting



Dec 6, 2021

Secura Bio Announces New Data To Be Presented At The American Society Of Hematology


Nov 29, 2021

ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting


Nov 18, 2021

Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology


Nov 11, 2021

Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting


Nov 9, 2021

MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting



Nov 9, 2021

Aleta Biotherapeutics Announces ALETA-001 Presentation at 63rd ASH Annual Meeting


Nov 4, 2021

Biosight Announces Upcoming Presentation at the 63rd American Society of Hematology Annual Meeting


Nov 4, 2021

Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting


Nov 4, 2021

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed and Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition


Nov 4, 2021

Aruvant Announces ARU-1801 Data to be Presented at the 63rd American Society of Hematology (ASH) Annual Meeting



Nov 4, 2021

EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and HSC Transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition


Nov 4, 2021

Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting


Nov 3, 2021

Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting


Dec 7, 2020

Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation


Dec 7, 2020

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition



Dec 7, 2020

Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T


Dec 7, 2020

Phosplatin Therapeutics Presents Phase I Dose Escalation Data of PT-112 in Patients with Relapsed / Refractory Multiple Myeloma at ASH Annual Meeting


Dec 7, 2020

Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting


Dec 7, 2020

Aruvant's Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease


Dec 7, 2020

JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting



Dec 7, 2020

Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting


Dec 6, 2020

CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition


Dec 5, 2020

Imago BioSciences’ Bomedemstat (IMG-7289) Shows Sustained Clinical Activity in Phase 2 Interim Data for Treatment of Myelofibrosis


Dec 5, 2020

Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meeting


Dec 5, 2020

Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020



Dec 4, 2020

Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 62nd Annual Meeting of the American Society of Hematology (ASH)


Dec 3, 2020

Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting


Dec 2, 2020

Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting


Nov 26, 2020

MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting


Nov 20, 2020

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December



Nov 19, 2020

Phosplatin Therapeutics Announces Presentation of Data from Phase I Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma at the ASH Annual Meeting


Nov 10, 2020

Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020


Nov 5, 2020

Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting


Nov 5, 2020

Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting


Nov 5, 2020

Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting



Nov 4, 2020

NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting


Nov 4, 2020

Gracell Biotechnologies Announces Two Oral Presentations at the ASH Annual Meeting and Exposition 2020


Nov 4, 2020

Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition


Nov 4, 2020

Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd American Society of Hematology (ASH) Annual Meeting


Oct 12, 2020

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting USA - English USA - English



Oct 12, 2020

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting


Dec 11, 2019

Fully-human BCMA CAR-T Clinical Results for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASH Annual Meeting


Dec 10, 2019

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting


Dec 9, 2019

Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting


Dec 9, 2019

WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition



Dec 9, 2019

STORM Therapeutics' Collaborator Awarded ASH-BSH Abstract Achievement Award at the 61st ASH Annual Meeting and Exposition


Dec 9, 2019

Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting


Dec 9, 2019

Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting


Dec 9, 2019

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting


Dec 9, 2019

FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions and Mutation Clearance in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome



Dec 9, 2019

Jasper Therapeutics Announces Upcoming Data Presentation on Lead Program, JSP191, at 61st American Society of Hematology (ASH) Annual Meeting and Exposition


Dec 8, 2019

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting


Dec 8, 2019

Aurora Bio, Inc Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition


Dec 7, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)


Dec 6, 2019

Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition



Dec 6, 2019

Talaris Therapeutics to Present at American Society of Hematology (ASH) Annual Meeting


Dec 6, 2019

Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to Transform Curative Hematopoietic Cell Transplants


Dec 3, 2019

Data on Rafael Pharmaceuticals’ CPI-613 (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting and Exposition


Dec 3, 2019

Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613 (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting and Expos


Dec 3, 2019

Eureka Therapeutics to Present New Clinical Data of anti-CD19 ARTEMIS™ 3.0 T-cell Therapy at 2019 ASH Annual Meeting



Dec 3, 2019

FORMA Therapeutics Announces Upcoming Presentations at the 31st Annual Piper Jaffray Healthcare Conference and the 2019 ASH Annual Meeting


Dec 2, 2019

Aleta Biotherapeutics Announces Oral Presentation at the 61st American Society of Hematology Annual Meeting (ASH)


Nov 22, 2019

Aurora Bio, Inc. Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition


Nov 18, 2019

Nurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting


Nov 15, 2019

Gracell Announces Five Presentations at the Annual Meeting of American Society of Hematology (ASH)



Nov 14, 2019

ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)


Nov 6, 2019

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition


Nov 6, 2019

ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting


Nov 6, 2019

MaaT Pharma to Present Initial Results with its Lead Microbiota Biotherapeutic in Intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting


Nov 6, 2019

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting



Nov 6, 2019

Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders


Nov 6, 2019

Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs


Nov 6, 2019

Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting


Oct 25, 2019

Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to be Presented at the 61st American Society of Hematology Annual Meeting & Exposition


Oct 25, 2019

Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to be Presented at the 61st American Society of Hematology Annual Meeting and Exposition



Dec 3, 2018

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting


Dec 3, 2018

Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting


Dec 3, 2018

Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma


Dec 3, 2018

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting


Dec 3, 2018

NeoImmuneTech Presents Hyleukin-7 and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting



Dec 3, 2018

Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology


Dec 2, 2018

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego


Dec 1, 2018

Petra Pharma Presents Preclinical PIP4K2 Inhibitor Data as a Potential Treatment for Hematologic Malignancies at the 2018 American Society of Hematology Annual Meeting


Nov 30, 2018

Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting


Nov 29, 2018

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting



Nov 29, 2018

Triumvira Immunologics Announces Presentation of Key Preclinical Data on TAC Technology at American Society of Hematology


Nov 26, 2018

WindMIL Therapeutics Announces Data on Marrow-Infiltrating Lymphocytes Selected for Poster Presentation at 60th American Society of Hematology Annual Meeting


Nov 14, 2018

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting


Nov 14, 2018

ADC Therapeutics kündigt Präsentationen auf der 60. Jahrestagung der American Society of Hematology (ASH) an


Nov 2, 2018

MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting



Nov 2, 2018

Tolero Pharmaceuticals to Highlight New Data Evaluating Investigational Agents Alvocidib and TP-1287 at 2018 American Society of Hematology Annual Meeting


Nov 2, 2018

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting


Nov 1, 2018

WUGEN Announces Presentations at American Society of Hematology Annual Meeting


Dec 11, 2017

Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting


Dec 11, 2017

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301



Dec 11, 2017

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402


Dec 11, 2017

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials


Dec 7, 2017

Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting and Exposition


Dec 5, 2017

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA


Nov 15, 2017

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting



Nov 13, 2017

Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)


Nov 8, 2017

Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease, at ASH Annual Meeting


Nov 2, 2017

Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting


Nov 2, 2017

Bioniz Therapeutics to Present New Data at the 2017 ASH Annual Meeting


Nov 1, 2017

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting



Dec 6, 2016

Alopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual Meeting


Dec 5, 2016

Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting


Dec 1, 2016

Karolinska Development company Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego


Dec 1, 2016

Positive Pre-Clinical and Clinical Data for Nohla Therapeutics’ Cell Product to Be Presented at the 58th ASH Annual Meeting and Exposition


Nov 29, 2016

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting



Nov 29, 2016

Emmaus Life Sciences Receives Notice of FDA PDUFA Date for Investigational L-glutamine Treatment for Sickle Cell Disease


Nov 3, 2016

Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting


Nov 3, 2016

Abstract Describing Imara’s Sickle Cell Disease Therapy, IMR-687, Accepted for Oral Presentation at the ASH Annual Meeting


Dec 10, 2015

Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting


Dec 7, 2015

Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)



Dec 7, 2015

Alopexx Oncology Presents Encouraging Phase I/II Clinical Data On DI-Leu16-IL2 At The American Society Of Hematology Annual Meeting


Dec 5, 2015

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference


Oct 26, 2015

BioSight Will Present Interim Results From a Phase 1/2 Clinical Trial of Astarabine for Treating Acute Leukemia at the ASH Annual Meeting 2015


Dec 8, 2014

Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco


Nov 24, 2014

Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Trial Data At 56th American Society Of Hematology Annual Meeting



Nov 6, 2014

Promedior Announces Presentation of Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming ASH Annual Meeting


Dec 20, 2012

Gliknik Announces Interim Clinical Data From Use Of Its Immunomodulator Drug Candidate In Multiple Myeloma Patients